From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement-Reference-Cited by-同舟云学术

From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement

Published:2020-11-19 Issue:23 Volume:63 Page:14780-14804
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Mostinski Yelena¹,Heynen Guus J. J. E.²,López-Alberca Maria Pascual¹,Paul Jerome¹,Miksche Sandra¹,Radetzki Silke¹,Schaller David³,Shanina Elena⁴,Seyffarth Carola¹,Kolomeets Yuliya¹,Ziebart Nandor¹,de Schryver Judith¹,Oestreich Sylvia¹,Neuenschwander Martin¹,Roske Yvette²,Heinemann Udo²,Rademacher Christoph⁴^ORCID,Volkamer Andrea³^ORCID,von Kries Jens Peter¹,Birchmeier Walter²,Nazaré Marc¹^ORCID

Affiliation:

1. Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany

2. Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin, Germany

3. Charité−Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

4. Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Am Mühlenberg, 1, 14476 Potsdam, Germany

Funder

Minerva Foundation

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link